Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2015

01.06.2015 | Original Article

Racial Differences in the Prevalence of Celiac Disease in the US Population: National Health and Nutrition Examination Survey (NHANES) 2009–2012

verfasst von: Houssam E. Mardini, Philip Westgate, Alla Y. Grigorian

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Aim

To provide an estimate of the prevalence of celiac disease by race/ethnic origin in large sample of US population.

Methods

Data from the 2009–2010 and 2011–2012 NHANES were combined and analyzed. The NHANES is a nationally representative survey with oversampling of certain minorities. Sample-based frequencies were reported and weighted frequencies were used to estimate prevalence.

Results

A total of 14,701 participants were checked for tissue transglutaminase (tTG) and endomysial (EMA) IgA antibodies. Seventy-four participants had positive tTG and/or EMA corresponding to prevalence of 0.79 % (95 % CI 0.54–1.04 %). Non-Hispanic white were more likely to be positive for both compared with other races (72.0 vs 31.7 %; p = 0.010) and less likely to be weakly positive for tTG but positive for EMA (3.6 vs 26.4 %; p = 0.03). The prevalence of positive serology according to race was as follows: 1.08 % (95 % CI 0.70–1.45 %) in non-Hispanic white, 0.23 % (95 % CI 0.03–0.43 %) in Mexican, 0.22 % (95 % CI 0.01–0.44 %) in non-Hispanic black, 0.38 % (95 % CI 0.00–0.89 %) in “other Hispanic,” and 0.15 % (95 % CI 0.00–0.34 %) in other races including multiracial and undeterminable in non-Hispanic Asian due to the presence of only one positive EMA test. 0.9 % of the NHANES sample participants followed gluten-free diet. Of this group of participants, 85 % were never diagnosed with celiac disease and 99 % of them had negative celiac disease serology.

Conclusions

Potentially 0.79 % of the general US population demonstrate serologic evidence of celiac disease autoimmunity. The prevalence is 4–8 times higher among non-Hispanic white compared with other races. Close to 1 % of the population is electively following gluten-free diet despite having little evidence of the disease.
Literatur
1.
Zurück zum Zitat Evans KE, Sanders DS. Celiac disease. Gastroenterol Clin N Am. 2012;41:639–650.CrossRef Evans KE, Sanders DS. Celiac disease. Gastroenterol Clin N Am. 2012;41:639–650.CrossRef
2.
Zurück zum Zitat Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007;26:1217–1225.CrossRefPubMed Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007;26:1217–1225.CrossRefPubMed
3.
Zurück zum Zitat Ludvigsson JF, Rubio-Tapia A, van Dyke CT, et al. Increasing incidence of celiac disease in a North American population. Am J Gastroenterol. 2013;108:818–824.CrossRefPubMedCentralPubMed Ludvigsson JF, Rubio-Tapia A, van Dyke CT, et al. Increasing incidence of celiac disease in a North American population. Am J Gastroenterol. 2013;108:818–824.CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol. 2010;105:2520–2524.CrossRefPubMed Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol. 2010;105:2520–2524.CrossRefPubMed
6.
Zurück zum Zitat Fasano A, Berti I, Gerrarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286–292.CrossRefPubMed Fasano A, Berti I, Gerrarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286–292.CrossRefPubMed
7.
Zurück zum Zitat Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012;107:1538–1544. Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012;107:1538–1544.
15.
Zurück zum Zitat Talley NJ, Valdovinos M, Petterson TM, et al. Epidemiology of celiac sprue: a community-based study. Am J Gastroenterol. 1994;89:843–846.PubMed Talley NJ, Valdovinos M, Petterson TM, et al. Epidemiology of celiac sprue: a community-based study. Am J Gastroenterol. 1994;89:843–846.PubMed
16.
Zurück zum Zitat Murray JA, Van Dyke C, Plevak MF, et al. Trends in the identification and clinical features of celiac disease in a North American community, 1950–2001. Clin Gastroenterol Hepatol. 2003;1:19–27.CrossRefPubMed Murray JA, Van Dyke C, Plevak MF, et al. Trends in the identification and clinical features of celiac disease in a North American community, 1950–2001. Clin Gastroenterol Hepatol. 2003;1:19–27.CrossRefPubMed
17.
Zurück zum Zitat West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut. 2003;52:960–965.CrossRefPubMedCentralPubMed West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut. 2003;52:960–965.CrossRefPubMedCentralPubMed
18.
19.
Zurück zum Zitat Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42:530–538.CrossRefPubMed Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42:530–538.CrossRefPubMed
20.
Zurück zum Zitat Kang JY, Kang AH, Green A, et al. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. Aliment Pharmacol Ther. 2013;38:226–245.CrossRefPubMed Kang JY, Kang AH, Green A, et al. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. Aliment Pharmacol Ther. 2013;38:226–245.CrossRefPubMed
21.
Zurück zum Zitat Remes-Troche JM, Ramírez-Iglesias MT, Rubio-Tapia A, et al. Celiac disease could be a frequent disease in Mexico: prevalence of tissue transglutaminase antibody in healthy blood donors. J Clin Gastroenterol. 2006;40:697–700.CrossRefPubMed Remes-Troche JM, Ramírez-Iglesias MT, Rubio-Tapia A, et al. Celiac disease could be a frequent disease in Mexico: prevalence of tissue transglutaminase antibody in healthy blood donors. J Clin Gastroenterol. 2006;40:697–700.CrossRefPubMed
22.
Zurück zum Zitat Sher KS, Fraser RC, Wicks AC, et al. High risk of coeliac disease in Punjabis. Epidemiological study in the south Asian and European populations of Leicestershire. Digestion. 1993;54:178–182.CrossRefPubMed Sher KS, Fraser RC, Wicks AC, et al. High risk of coeliac disease in Punjabis. Epidemiological study in the south Asian and European populations of Leicestershire. Digestion. 1993;54:178–182.CrossRefPubMed
23.
Zurück zum Zitat Ji J, Ludvigsson JF, Sundquist K, et al. Incidence of celiac disease among second-generation immigrants and adoptees from abroad in Sweden: evidence for ethnic differences in susceptibility. Scand J Gastroenterol. 2011;46:844–848.CrossRefPubMed Ji J, Ludvigsson JF, Sundquist K, et al. Incidence of celiac disease among second-generation immigrants and adoptees from abroad in Sweden: evidence for ethnic differences in susceptibility. Scand J Gastroenterol. 2011;46:844–848.CrossRefPubMed
25.
Zurück zum Zitat Rubio-Tapia A, Hill ID, Kelly CP, et al. American College of Gastroenterology Clinical Guideline: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656–677.CrossRefPubMedCentralPubMed Rubio-Tapia A, Hill ID, Kelly CP, et al. American College of Gastroenterology Clinical Guideline: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656–677.CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Hischenhuber C, Crevel R, Jarry B, et al. Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther. 2006;23:559–575.CrossRefPubMed Hischenhuber C, Crevel R, Jarry B, et al. Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther. 2006;23:559–575.CrossRefPubMed
27.
Zurück zum Zitat Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. 2013;62:996–1004.CrossRefPubMedCentralPubMed Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. 2013;62:996–1004.CrossRefPubMedCentralPubMed
Metadaten
Titel
Racial Differences in the Prevalence of Celiac Disease in the US Population: National Health and Nutrition Examination Survey (NHANES) 2009–2012
verfasst von
Houssam E. Mardini
Philip Westgate
Alla Y. Grigorian
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3514-7

Weitere Artikel der Ausgabe 6/2015

Digestive Diseases and Sciences 6/2015 Zur Ausgabe

UNM Clinical Case Conferences

An Intimate Cause of Proctocolitis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.